toxoplasmosi
caus
age
group
includ
young
children
adult
global
one
parasit
diseas
zoonosi
infect
toxoplasma
gondii
gondii
gondii
induc
chronic
infect
variou
site
human
bodi
also
caus
brain
infect
central
nervou
system
zoonot
parasitosi
addit
gondii
uniqu
infecti
subcellular
organel
includ
apicoplast
conoid
rhoptri
dens
granul
micronem
gener
gondii
form
uniqu
prolif
membran
parasitophor
vacuol
membran
pvm
includ
reticular
network
rn
prolifer
invas
host
cell
grow
recent
sever
drug
develop
inhibit
gondii
use
treat
toxoplasmosi
patient
clinic
howev
side
effect
still
clear
clinic
also
expos
drugresist
gradual
aspect
pyrimethamin
use
treat
toxoplasmosi
block
synthesi
tetrahydrofol
acid
dihydrofol
reductas
dhfr
effect
inhibit
dihydrofol
reductas
gondii
inhibit
consist
synthesi
dna
andor
rna
prolifer
protozoa
speci
includ
malaria
recent
report
variou
extract
andor
natur
product
deriv
medicin
plant
possibl
use
medic
resourc
treat
infecti
viru
diseas
includ
middl
east
respiratori
syndrom
mer
dengu
fever
zika
fever
well
show
vitro
inhibitori
effect
chronic
diseas
hepat
cancer
tuberculosi
although
variou
extract
deriv
tradit
medicin
plant
natur
compound
report
indic
antit
gondii
activitieseffect
effect
drug
next
gener
treatment
toxoplasmosi
caus
gondii
yet
develop
clinic
studi
furthermor
despit
variou
effort
develop
antiparasit
drug
zoonot
parasitosi
deriv
parasit
consist
worsen
crisi
public
health
worldwid
aspect
variou
research
discov
effect
drug
toxoplasmosi
studi
new
substanc
rel
low
toxic
safeti
urgent
requir
inhibit
zoonosi
ursol
acid
bioactiv
substanc
contain
variou
medicin
plant
use
natur
resourc
orient
medicin
folk
medicin
also
known
varieti
effect
bioactiv
anxiolyt
activ
antiangiogen
activ
antiepilept
effect
furthermor
ursol
acid
effect
induc
extens
bioactiv
includ
antiinflammatori
anticanc
antioxid
antimicrobi
antitubercular
effect
well
caus
strong
inhibitori
effect
arthrit
autoimmun
diseas
studi
show
ursol
acid
induc
variou
physiolog
activ
vitro
vivo
also
possibl
antiparasit
candid
drug
howev
studi
regard
antit
gondii
activ
ursol
acid
report
yet
addit
novel
andor
effect
drug
treatment
toxoplasmosi
develop
yet
even
though
signific
result
regard
antit
gondii
activ
report
variou
studi
global
reason
studi
start
hypothesi
ursol
acid
may
effect
inhibit
modul
proliferationgrowth
gondii
caus
toxoplasmosi
human
studi
carri
evalu
antit
gondii
effect
ursol
acid
known
bioactiv
substanc
determin
potenti
promis
candid
substanc
develop
novel
antitoxoplasmosi
drug
gondii
caus
parasit
diseas
anim
human
well
uniqu
micro
network
system
specif
structur
includ
variou
microorganel
mitochondria
rhoptri
micronem
evalu
antiparasit
activ
effect
ua
prolifer
growth
gondii
use
mtt
assay
ua
show
antit
gondii
activ
rang
gondiiinfect
cell
incub
differ
concentr
ua
h
viabil
markedli
decreas
dose
depend
manner
tabl
tabl
addit
ua
effect
inhibit
prolifer
growth
gondiiinfect
cell
compar
sf
particular
gondiinfect
cell
treat
ua
show
signific
decreas
gondii
includ
gondii
fragment
well
morpholog
chang
cell
shrinkag
cell
fragment
compar
untreat
gondiiinfect
cell
data
shown
suggest
ua
antiparasit
activ
inhibitori
effect
gondi
infect
cell
tabl
furthermor
ua
effect
inhibit
viabil
parasit
direct
inhibit
gondii
compar
sf
strongli
demonstr
select
inhibitori
effect
gondii
parasit
sr
measur
less
concentr
figur
inhibitori
concentr
valu
ua
gondii
gondiiinfect
cell
measur
respect
result
demonstr
ua
strongli
induc
antiprolifer
activ
gondii
infect
host
cell
effect
block
gondii
well
direct
inhibitori
action
gondii
gondii
induc
antiapoptot
step
featur
inactiv
apoptot
protein
prolif
phase
host
cell
show
uniqu
parasit
lifecycl
gondii
particular
format
pvm
acceler
timedepend
manner
cell
invas
gondii
reason
investig
inhibit
pvm
caus
interact
gondii
ua
prolifer
stage
gondii
host
cell
shown
figur
pvm
format
nucleu
gondii
markedli
decreas
gondiiinfect
host
cell
treat
ua
sf
respect
chang
clearli
observ
uv
fluoresc
result
indic
inhibitori
effect
ua
pvm
format
viabil
gondii
therefor
result
show
substanti
evid
ua
effect
inhibit
block
pvm
form
gondii
prolif
stage
well
prolifer
gondii
infect
host
cell
cell
invas
gondii
induc
infecti
symptom
diseas
lymphadenopathi
brain
injuri
particularli
human
zoonot
parasit
infect
human
anim
aspect
evalu
antiprolif
effect
parasit
inhibitori
activ
ua
viabil
gondii
gondiiinfect
mice
mice
care
observ
experiment
period
inject
gondii
treat
ua
h
mention
gondiiinfect
mice
treat
differ
concentr
ua
show
higher
activ
viabil
gondiiinfect
mice
mice
indic
dynam
energet
activ
normal
group
particular
clearli
confirm
signific
differ
surviv
rate
gondiiinfect
mice
infect
mice
treat
ua
howev
gondiiinfect
mice
treat
ua
show
effect
ua
consist
maintain
surviv
infect
mice
decreas
day
result
suggest
death
mice
may
owe
tissu
damag
cytolysi
invas
gondii
loss
bodi
weight
mice
furthermor
symptom
side
effect
loss
bodi
weight
observ
induc
group
treat
ua
experiment
period
figur
result
show
effect
clear
evid
regard
effect
antit
gondii
compound
indic
clariti
regard
result
fusion
method
vitro
vivo
result
demonstr
ua
select
antiparasit
activ
strongli
caus
antit
gondii
effect
well
suppress
viabil
effect
inhibit
gondii
recent
effort
treatment
neglect
infecti
diseas
attempt
variou
field
particular
global
support
organ
includ
bill
melinda
gate
foundat
global
pharmaceut
support
studi
develop
novel
drug
effect
treat
block
zoonosi
malaria
tuberculosi
well
infecti
diseas
includ
aid
zika
ebola
mer
sar
care
focu
neglect
infecti
diseas
consist
caus
variou
pathway
infect
factor
perspect
gondii
caus
fetu
seriou
infecti
diseas
retinochoroid
hydrocephalu
cerebr
calcif
fetu
infect
pregnanc
well
induc
symptom
lymphadenopathi
meningoenceph
brain
acquir
infect
zoonot
parasit
infect
human
anim
also
induc
seriou
complic
immun
defici
patient
hiv
patient
one
infecti
parasit
induc
parasit
zoonosi
may
induc
interact
parasit
prolifer
growth
parasit
relationship
symbiosi
host
aspect
gondii
inhibit
defens
mechan
cytokin
releas
host
cell
invas
also
suppress
product
protect
system
activ
immunerespons
furthermor
known
block
signal
transport
pathway
activ
antiparasit
system
resist
gondii
invas
host
cell
well
suppress
apoptot
signal
cell
arrest
pathway
earli
apoptot
stage
host
cell
cell
invas
moreov
gondii
promot
inactiv
cell
cycl
initi
apoptot
mediat
prolif
phase
gondii
form
pvm
gondii
host
cell
rapidli
acceler
prolifer
gondii
pvm
studi
evalu
antiparasit
activityeffect
ua
inhibit
prolifer
gondii
confirm
viabil
gondii
parasit
infect
gondiiinfect
vitro
system
anim
test
present
studi
express
pvm
infect
host
cell
significantli
increas
compar
gondiiinfect
cell
treat
ua
sf
uninfect
cell
hand
prolifer
gondii
pvm
markedli
inhibit
gondiiinfect
cell
treat
ua
compar
gondiiinfect
cell
addit
evalu
antit
gondii
activ
ua
gondiiinfect
mice
inject
gondii
treat
ua
mice
show
vital
viabil
uninfect
control
group
without
loss
bodi
weight
cytotox
experi
particular
recent
report
ua
antiprotozoa
effect
leishmania
amazonesi
leishmania
infantum
caus
leishmaniasi
among
neglect
tropic
diseas
mechan
action
associ
program
cell
death
nitric
oxid
product
aspect
antit
gondii
effect
ua
suggest
ua
may
induc
antiprolifer
growth
inhibitori
action
gondii
mechan
action
caus
nitric
oxid
product
program
cell
death
gondii
infect
host
cell
taken
togeth
result
indic
express
pvm
gondiiinfect
cell
select
inhibit
block
host
cell
treat
ua
well
significantli
increas
infect
cell
furthermor
gondiiinfect
mice
treat
ua
show
stabl
lifecycl
surviv
rate
compar
infect
posit
group
experiment
period
result
clearli
provid
inhibitori
effect
activ
compound
gondii
indic
whether
ua
induc
direct
inhibit
gondii
increas
surviv
mice
effect
block
inhibit
viabil
gondii
fetal
bovin
serum
fb
antibiot
trypsinedta
purchas
invitrogen
corpor
waltham
usa
mtt
bromid
thiazolyl
blue
rpmi
medium
sulfadiazin
dimethyl
sulfoxid
dmso
phosphat
buffer
salin
pb
trypan
blue
solut
hoechst
purchas
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
chemic
reagent
purchas
merck
chemic
co
ltd
darmstadt
germani
sigmaaldrich
chemic
co
ltd
st
loui
mo
usa
balbcmic
six
week
n
purchas
daehan
biolink
co
ltd
chungcheongbukdo
korea
anim
kept
hlightdark
cycl
control
environ
central
anim
care
facil
food
water
provid
ad
libitum
anim
facil
strictli
maintain
accord
guidelin
nation
institut
health
care
use
laboratori
anim
antit
gondii
drug
sulfadiazin
sf
dissolv
dmso
ursol
acid
ua
also
dissolv
dmso
concentr
mgml
accord
manufactur
instruct
sulfadiazin
use
standard
drug
evalu
whether
ursol
acid
antiparasit
effect
activ
gondii
compound
filter
use
membran
syring
filter
roshi
kaisha
ltd
tokyo
japan
use
store
deepfreez
use
glioma
cell
cell
purchas
korean
cell
line
bank
seoul
nation
univers
cell
cultur
rpmi
medium
contain
mm
lglutamin
supplement
fetal
bovin
serum
fb
unitsml
penicillin
streptomycin
biofluid
rockvil
md
usa
humidifi
atmospher
contain
air
rh
strain
gondii
suspend
pb
inject
abdomin
caviti
balbcmous
five
day
inject
gondii
collect
periton
fluid
mous
kept
abdomin
caviti
mice
use
studi
vitro
studi
cell
infect
gondii
cell
gondii
evalu
inhibitori
effect
ua
viabil
gondii
investig
viabil
gondii
expos
ua
sf
briefli
gondii
seed
well
plate
gondii
incub
differ
concentr
ua
sf
h
respect
viabil
determin
mtt
assay
determin
whether
ua
direct
antiparasit
activ
andor
effect
gondii
surviv
rate
sr
gondii
calcul
follow
sr
oddrugtest
well
odblank
odcontrol
odblank
optic
densiti
od
measur
wavelength
nm
use
elisa
leader
cell
seed
well
plate
incub
h
cell
infect
gondii
tachyzoiteswel
gondiiinfect
cell
treat
ua
sf
h
respect
morpholog
chang
gondiiinfect
host
cell
observ
light
microscop
nikon
eclips
te
tokyo
japan
antit
gondii
effect
ua
gondiiinfect
cell
evalu
use
hoechst
accord
nuclear
stain
method
describ
previous
cell
seed
onto
cover
slip
well
plate
cellswel
infect
gondii
tachyzoiteswel
h
gondiiinfect
cell
incub
ua
sf
h
respect
wash
pb
gondiiinfect
cell
fix
pb
contain
formaldehyd
min
wash
pb
stain
final
concentr
hoechst
st
loui
mo
usa
min
dark
nuclear
stain
cell
wash
pb
three
time
nuclear
chang
observ
uv
fluoresc
microscop
nikon
eclips
te
tokyo
japan
cell
seed
onto
cover
slip
well
plate
cellswel
infect
gondii
tachyzoiteswel
gondiiinfect
cell
incub
ua
sf
h
respect
wash
pb
fix
formaldehyd
min
vv
triton
min
cell
block
pb
contain
bsa
h
room
temperatur
wash
mous
monoclon
antipvm
antibodi
dilut
vv
use
bsapb
cell
incub
antipvm
antibodi
solut
room
temperatur
h
wash
goat
antimous
iggfitcconjug
secondari
antibodi
dilut
vv
use
pb
ad
well
cell
incub
room
temperatur
h
wash
pb
everi
min
four
time
fluoresc
observ
uv
fluoresc
microscop
nikon
eclips
te
tokyo
japan
twentyf
anim
week
n
divid
normal
n
experiment
group
four
group
n
gondii
seed
well
plate
incub
differ
concentr
ua
h
respect
gondii
treat
compound
harvest
inject
abdomin
caviti
mous
experi
group
wash
pb
three
time
pellet
suspend
pb
inject
abdomin
caviti
balbcmous
experiment
group
gondiiinfect
mice
untreat
ua
use
infect
posit
group
anim
kept
central
anim
care
facil
experi
result
express
mean
sd
statist
analysi
data
perform
use
student
ttest
analysi
varianc
anova
p
consid
statist
signific
result
studi
demonstr
ua
antit
gondii
activ
caus
direct
inhibit
gondii
also
caus
antiparasit
effect
gondii
strongli
inhibit
prolifer
growth
gondii
infect
host
cell
addit
result
show
clearli
first
time
ua
antit
gondii
effect
consist
induc
surviv
gondiiinfect
mice
therefor
studi
provid
substanti
result
potenti
ua
util
promis
candid
substanc
antit
gondii
drug
develop
nextgener
gondiiinfect
cell
infectedmic
model
addit
ua
suggest
novel
perspect
approach
antit
gondii
drug
develop
show
need
studi
regard
safeti
andor
efficaci
toxoplasmosi
preclin
studi
near
futur
